Cardiotoxicity of Trastuzumab Emtansine (T-DM1): A Single-center Experience

dc.contributor.authorAcibuca, Aynur
dc.contributor.authorSezer, Ahmet
dc.contributor.authorYilmaz, Mustafa
dc.contributor.authorSumbul, Ahmet Taner
dc.contributor.authorDemircan, Senol
dc.contributor.authorMuderrisoglu, Ibrahim Haldun
dc.contributor.authorOzyilkan, Ozgur
dc.contributor.authorID0000-0002-3444-8845en_US
dc.contributor.pubmedID34898302en_US
dc.contributor.researcherIDABG-4047-2020en_US
dc.date.accessioned2022-06-23T07:12:04Z
dc.date.available2022-06-23T07:12:04Z
dc.date.issued2021
dc.description.abstractObjective New anti-cancer drugs promise to increased survival benefits and reduce adverse events. Trastuzumab emtansine (T-DM1) is a novel anti-human epidermal growth factor receptor 2 agent that has shown minimal cardiotoxicity in clinical trials. However, data on real-life outcomes are required. Methods A retrospective review of our center's medical records was performed, including female patients aged >= 18 years with a diagnosis of metastatic breast cancer who were treated with T-DM1. Descriptive statistics were used to investigate clinical features that could increase the risk of cardiotoxicity. Cardiotoxicity was determined by comparing pre and post-T-DM1 echocardiogram results and was defined as a decrease in the left ventricular ejection fraction (LVEF) >10% to below 55%. Results Data from 41 female patients with a mean age of 52 +/- 11.5 years were evaluated. A significant LVEF decrease (from 59% to 33%) was observed in one patient during T-DM1 treatment. Further investigation showed that this decrease was due to underlying coronary artery disease, and LVEF recovered to the baseline value after coronary revascularization. Conclusion T-DM1 seems to be safe in terms of cardiotoxicity. Real-life data with a larger sample size are still needed to confirm the cardiac safety of T-DM1.en_US
dc.identifier.endpage8en_US
dc.identifier.issn0300-0605en_US
dc.identifier.issue12en_US
dc.identifier.scopus2-s2.0-85121351478en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://journals.sagepub.com/doi/pdf/10.1177/03000605211053755
dc.identifier.urihttp://hdl.handle.net/11727/7122
dc.identifier.volume49en_US
dc.identifier.wos000730597300001en_US
dc.language.isoengen_US
dc.relation.isversionof10.1177/03000605211053755en_US
dc.relation.journalJOURNAL OF INTERNATIONAL MEDICAL RESEARCHen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBreast canceren_US
dc.subjectcardiotoxicityen_US
dc.subjecttrastuzumab emtansineen_US
dc.subjectleft ventricular ejection fractionen_US
dc.subjectechocardiogramen_US
dc.subjectmetastatic breast canceren_US
dc.titleCardiotoxicity of Trastuzumab Emtansine (T-DM1): A Single-center Experienceen_US
dc.typearticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
03000605211053755.pdf
Size:
278.09 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: